Biota Announces Royalties from Inavir® and Relenza™ for Q4 and F2011
August 01 2011 - 9:00AM
Business Wire
Biota Holdings Limited (ASX:BTA) announces that it has received
written notifications from GlaxoSmithKline (GSK) regarding
royalties for Relenza™ and from Daiichi Sankyo for Inavir®.
Indicative royalties from Relenza™ were $1.8m during the three
months ended 30 June 2011. F2011 actual royalties are $6.6m.
Royalties from of Inavir® were AUD 160k during the three months
ended 30 June 2011, on sales of JPY 390m.
Indicative royalties and sales advised by GSK by quarter for the
full financial year, are summarised below:
Q1 Q2
Q3 Q4
Adjustment* Total Indicative royalties
$m 2.1 1.2 1.0
1.8 0.5 6.6 Indicative sales $m
29.6 17.9 14.1
18.0 - 79.6
* Adjusts indicative royalties reported during the year to
actual and includes exchange rate corrections where
appropriate.
Royalties and sales advised by Daiichi Sankyo since launch in
October 2010, by quarter are summarised below:
Q2 Q3
Q4 Total Indicative royalties
AUDm 1.16 1.60 0.16
2.92 Indicative sales JPYbn 2.8
3.9 0.4 7.1
Biota will report actual royalties from Inavir® of AUD 2.92m for
the year to 30 June 2011.
About Biota
Biota is a leading anti-infective drug development company based
in Melbourne Australia, with key expertise in respiratory diseases,
particularly influenza. Biota developed the first-in-class
neuraminidase inhibitor, zanamivir, subsequently marketed by
GlaxoSmithKline as Relenza™. Biota research breakthroughs include a
series of candidate drugs aimed at treatment of respiratory
syncytial virus (RSV) disease and Hepatitis C (HCV) virus
infections. Biota has clinical trials underway with its lead
compound for human rhinovirus (HRV) infection in patients with
compromised respiration or immune systems.
In addition, Biota and Daiichi Sankyo co-own a range of second
generation influenza antivirals, of which the lead product lnavir®,
is approved for marketing in Japan. Biota holds a contract from the
US Office of Biomedical Advanced Research and Development Authority
(BARDA) for the advanced development of laninamivir in the USA.
Relenza™ is a registered trademark of the GlaxoSmithKline group
of companies.
Inavir® is registered to Daiichi Sankyo.
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Sep 2024 to Oct 2024
Biota Holdings (ASX:BTA)
Historical Stock Chart
From Oct 2023 to Oct 2024